3K3A-Activated Protein C Prevents Microglia Activation, Inhibits NLRP3 Inflammasome and Limits Ocular Inflammation
Authors:
- Dahlia PalevskiDPDahlia Palevski
- Gil Ben-DavidGBGil Ben-David
- Yehonatan WeinbergerYWYehonatan Weinberger
- Rabeei Haj DaoodRDRabeei Haj Daood
- José A. FernándezJFJosé A. Fernández
- Ivan BudnikIBIvan Budnik
- Sarina Levy-MendelovichSLSarina Levy-Mendelovich
- Gili KenetGili Kenet
- Yael NisgavYNYael Nisgav
- Dov WeinbergerDWDov Weinberger
- John H. GriffinJGJohn H. Griffin
- Tami LivnatTLTami Livnat
Open Access
- 17 November 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14196
Abstract
3K3A-Activated Protein C (APC) is a recombinant variant of the physiological anticoagulant APC with pleiotropic cytoprotective properties albeit without the bleeding risks. The anti-inflammatory activities of 3K3A-APC were demonstrated in multiple preclinical injury models, including various neurological disorders. We determined the ability of 3K3A-APC to inhibit ocular inflammation in a murine model of lipopolysaccharide (LPS)-induced uveitis. Leukocyte recruitment, microglia activation, NLRP3 inflammasome and IL-1β levels were assessed using flow cytometry, retinal cryosection histology, retinal flatmount immunohistochemistry and vascular imaging, with and without 3K3A-APC treatment. LPS triggered robust inflammatory cell recruitment in the posterior chamber. The 3K3A-APC treatment significantly decreased leukocyte numbers and inhibited leukocyte extravasation from blood vessels into the retinal parenchyma to a level similar to controls. Resident microglia, which underwent an inflammatory transition following LPS injection, remained quiescent in eyes treated with 3K3A-APC. An inflammation-associated increase in retinal thickness, observed in LPS-injected eyes, was diminished by 3K3A-APC treatment, suggesting its clinical relevancy. Finally, 3K3A-APC treatment inhibited inflammasome activation, determined by lower levels of NLRP3 and its downstream effector IL-1β. Our results highlight the anti-inflammatory properties of 3K3A-APC in ocular inflammation and suggest its potential use as a novel treatment for retinal diseases associated with inflammation.Keywords
Funding Information
- Study of Blindness and Visual Disorders, Sackler Faculty of Medicine, Tel Aviv University
- National Institutes of Health (R01HL142975)
This publication has 54 references indexed in Scilit:
- Drotrecogin Alfa (Activated) in Adults with Septic ShockNew England Journal of Medicine, 2012
- The NLRP3 inflammasome is active but not essential in endotoxin-induced uveitisInflammation Research, 2011
- Neurodegenerative and Inflammatory Pathway Components Linked to TNF-α/TNFR1 Signaling in the Glaucomatous Human RetinaInvestigative Ophthalmology & Visual Science, 2011
- Microglial Activation in the Visual Pathway in Experimental Glaucoma: Spatiotemporal Characterization and Correlation with Axonal InjuryInvestigative Ophthalmology & Visual Science, 2010
- Species‐dependent neuroprotection by activated protein C mutants with reduced anticoagulant activityJournal of Neurochemistry, 2009
- The cytoprotective protein C pathwayBlood, 2006
- Two types of protease-activated receptors (PAR-1 and PAR-2) mediate calcium signaling in rat retinal ganglion cells RGC-5Brain Research, 2005
- Activated protein C variants with normal cytoprotective but reduced anticoagulant activityBlood, 2004
- Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C DeficiencySeminars in Thrombosis and Hemostasis, 1995
- Endotoxin-induced uveitis in rats as a model for human diseaseNature, 1980